Drug Type Small molecule drug |
Synonyms 安纳拉唑钠, KBP 3571, KBP-3571 + [1] |
Target |
Action inhibitors |
Mechanism Proton pump inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (21 Jun 2023), |
RegulationSpecial Review Project (China) |
Molecular FormulaC21H23N2NaO4S |
InChIKeyLHPWFLYRYFEIBN-UHFFFAOYSA-N |
CAS Registry- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Duodenal Ulcer | China | 21 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophagitis, Peptic | Phase 3 | China | 03 Jun 2025 | |
Gastroesophageal Reflux | Phase 2 | China | 01 Dec 2022 | |
Helicobacter pylori infection | Phase 1 | China | 10 Aug 2020 | |
Helicobacter pylori infection | Phase 1 | China | 10 Aug 2020 | |
Stomach Ulcer | Phase 1 | China | 14 Aug 2014 |
Phase 3 | 448 | czalzolxbx(csjawnhlix) = kpprsgdimg itslsqftfs (bnlezjbjxw ) | Positive | 30 Dec 2022 | |||
Rabeprazole 10 mg | czalzolxbx(csjawnhlix) = zhymnylhjl itslsqftfs (bnlezjbjxw ) | ||||||
Phase 2 | 150 | Rabeprazole 10 mg | gcoadbyqid(xenbrslyzx) = The incidence rates of adverse events were of no significant differences among the treatment groups jigheaemml (fdberkcwel ) View more | Positive | 01 Jan 2021 | ||